Passage Historical Cash Flow
PASG Stock | USD 1.13 0.46 68.66% |
Analysis of Passage Bio cash flow over time is an excellent tool to project Passage Bio future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Other Cashflows From Financing Activities of 68.5 M or Depreciation of 3.9 M as it is a great indicator of Passage Bio ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Passage Bio latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Passage Bio is a good buy for the upcoming year.
Passage |
About Passage Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Passage balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Passage's non-liquid assets can be easily converted into cash.
Passage Bio Cash Flow Chart
Add Fundamental
Capital Expenditures
Capital Expenditures are funds used by Passage Bio to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Passage Bio operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Passage Bio's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Passage Bio current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Passage Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.At this time, Passage Bio's Total Cashflows From Investing Activities is most likely to decrease significantly in the upcoming years. The Passage Bio's current Other Cashflows From Financing Activities is estimated to increase to about 68.5 M, while Free Cash Flow is projected to decrease to (82.3 M).
2021 | 2022 | 2023 | 2024 (projected) | Other Non Cash Items | 10.1M | 3.8M | 3.8M | 4.1M | Depreciation | 1.5M | 3.7M | 3.7M | 3.9M |
Passage Bio cash flow statement Correlations
Click cells to compare fundamentals
Passage Bio Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Currently Active Assets on Macroaxis
When determining whether Passage Bio is a strong investment it is important to analyze Passage Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Passage Bio's future performance. For an informed investment choice regarding Passage Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Passage Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Passage Bio. If investors know Passage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Passage Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.17) | Return On Assets (0.34) | Return On Equity (0.64) |
The market value of Passage Bio is measured differently than its book value, which is the value of Passage that is recorded on the company's balance sheet. Investors also form their own opinion of Passage Bio's value that differs from its market value or its book value, called intrinsic value, which is Passage Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Passage Bio's market value can be influenced by many factors that don't directly affect Passage Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Passage Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Passage Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Passage Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.